ClearStream's Intrepide stent:

ClearStream Technologies has CE marked its Intrepide drug-eluting stent (DES) for sale in Europe. The Wexford, Ireland-based firm will start selling the product in Europe and other CE-related markets through controlled registries, which will enable both early sales of Intrepide and gathering of post-marketing surveillance data. These are the ongoing ICLARITY ROW in Russia, Georgia and Bangladesh, and ICLARITY Europe, which will be launched in May. An earlier registry (PATIENT APT) found that 75% of patients implanted with Intrepide could discontinue anti-clotting drug therapy after three months, ClearStream says. There was a lower risk of late stent thrombosis with Intrepide than with the first generation DES, the firm added. Intrepide elutes the anti-platelet drug trapidil.

ClearStream Technologies has CE marked its Intrepide drug-eluting stent (DES) for sale in Europe. The Wexford, Ireland-based firm will start selling the product in Europe and other CE-related markets through controlled registries, which will enable both early sales of Intrepide and gathering of post-marketing surveillance data. These are the ongoing ICLARITY ROW in Russia, Georgia and Bangladesh, and ICLARITY Europe, which will be launched in May. An earlier registry (PATIENT APT) found that 75% of patients implanted with Intrepide could discontinue anti-clotting drug therapy after three months, ClearStream says. There was a lower risk of late stent thrombosis with Intrepide than with the first generation DES, the firm added. Intrepide elutes the anti-platelet drug trapidil.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By Ashley Yeo

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 
• By Natasha Barrow

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.